RxDoctor Payments Data

Jaime Armah, MD

Family Medicine · Lafayette, INNPI 1720574403

Payments from drug & device makers

$1,890in general payments, 2019–2025

Across 33 payments — averaging $57.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$516
  • Exact Sciences$274
  • Axsome Therapeutics, Inc.$157
  • Lilly USA, LLC$150
  • Inari Medical, Inc.$132
  • Smith+Nephew$124
  • plus $538 from 11 others

What the payments were for

  • Food & beverage$1,890100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,890 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$78,464
Medicare patients
200
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$92,295
EliquisApixaban35$36,485
OzempicSemaglutide26$31,345
JanuviaSitagliptin Phosphate27$29,792
MounjaroTirzepatide28$28,055
TrulicityDulaglutide20$19,134
TradjentaLinagliptin15$17,158
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,932
FarxigaDapagliflozin Propanediol13$9,696
MyrbetriqMirabegron12$8,831
Breo ElliptaFluticasone/Vilanterol15$5,917
DuleraMometasone/Formoterol11$3,839
Humalog Kwikpen U-100Insulin Lispro12$3,577
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,193
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$150$47,18848 claims
PfizerEliquis$39$36,48535 claims
MerckJanuvia, Dulera$13$33,63138 claims
Novo NordiskOzempic$33$31,34526 claims
AstraZenecaFarxiga$516$9,69613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →